Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
PwC's Next in Health cover art

PwC's Next in Health

PwC's Next in Health

Written by: PwC's Health Industries
Listen for free

About this listen

Hosted by Glenn Hunzinger, US Health Industries Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech, and healthcare. PwC business leaders discuss the latest trends and their impact on health industries, whether it is policy, AI, innovation, care delivery, business model reinvention, or bold moves shaping the future. If it is happening in health industries, we are talking about it.

© 2026 PwC Next in Health
Economics Hygiene & Healthy Living Management Management & Leadership
Episodes
  • 2026 Midterm Election Results: What's Next for US Healthcare Policy?
    Nov 13 2026

    What do the 2026 midterm election results mean for the future of US healthcare? With Democrats taking control of Congress and a Republican White House, healthcare affordability, access and industry oversight are expected to remain in focus. But how much policy change is actually possible? In this episode of Next in Health, PwC's Glenn Hunzinger is joined by Kelly Griffin, Tamil Sriram and Phil Sclafani to discuss where bipartisan progress may be possible, what increased congressional oversight could mean for the industry, and how payers, providers, pharmaceutical and medtech companies can prepare for what's next.

    Discussion highlights:

    • What's next for healthcare policy: How Democratic control of Congress could shift policy priorities, increase oversight and influence the debate heading into 2028.
    • Where bipartisan progress is possible: Potential action on affordability, drug pricing, cybersecurity, AI and regulatory modernization.
    • Implications for payers and providers: How coverage uncertainty, reimbursement pressures and increased scrutiny could affect financial and operational strategies.
    • What pharma and medtech should watch: Drug pricing, regulatory developments and the impact of customer financial pressures on access, adoption and investment.
    • How healthcare leaders can prepare: Why scenario planning, operational efficiency, consumer trust and demonstrating value remain critical amid policy uncertainty.

    Speakers:

    Glenn Hunzinger, US Health Industries Leader, PwC

    Kelly Griffin, Director, Health Policy and Intelligence Institute, PwC

    Tamil Sriram, Principal, Health Industries Risk & Regulatory, PwC

    Philip Sclafani, Principal, Pharmaceutical and Life Sciences, PwC

    Read our latest report: https://www.pwc.com/us/en/america-in-motion/2026-midterm-elections.html



    For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

    Show More Show Less
    19 mins
  • Bringing medtech innovation to market (Part 2)
    Oct 15 2026

    Bringing medtech innovation to market requires more than a breakthrough technology. It takes the right capital, evidence, reimbursement strategy, and path to scale. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill continue their conversation with Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, exploring what it takes to turn promising medtech innovation into sustainable growth and patient impact. From funding and clinical evidence to M&A, product-market fit, and capital efficiency, the conversation examines how founders, investors, and strategic players are navigating an increasingly complex market.

    Discussion highlights:

    • The evolving funding environment for early-stage medtech companies and what investors are looking for today
    • Why clinical, regulatory, and reimbursement strategies increasingly need to be considered together
    • The forces driving medtech M&A, including portfolio optimization, new buyers, and the need for growth
    • How companies and investors can build toward meaningful value inflection points and potential exits
    • The importance of capital discipline, investor alignment, strong leadership teams, and product-market fit
    • Where investors see the greatest opportunities for MedTech innovation over the next three to five years and beyond

    Speakers:

    Glenn Hunzinger, US Health Industries Leader, PwC
    Darshana Zaveri, Co-founder and Managing Partner, Catalyst Health Ventures
    Geoff Pardo, General Partner, Gilde Healthcare
    Brent Hill, Managing Director, Medtech Strategy, PwC


    For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

    Show More Show Less
    23 mins
  • The next wave of medtech innovation (Part 1)
    Oct 8 2026

    Medtech innovation is accelerating, creating new possibilities for how and where patients receive care. In this episode of PwC’s Next in Health, Glenn Hunzinger and Brent Hill are joined by Darshana Zaveri, co-founder and managing partner of Catalyst Health Ventures, and Geoff Pardo, general partner at Gilde Healthcare, for part one of a two-part conversation on the next wave of medtech innovation. From AI and connected care to less invasive technologies, robotics, and the shift beyond the hospital, the conversation explores the technologies and market trends reshaping medtech and where investors and innovators see the greatest opportunities ahead.

    Discussion highlights:

    • How medtech innovation is evolving toward less invasive, more scalable, and increasingly connected technologies
    • AI’s growing role in devices, clinical decision-making, and connected care
    • The shift from hospitals to ambulatory settings and the home and what it means for medtech companies
    • Emerging opportunities across neuromodulation, robotics, biomaterials, drug-device combinations, and remote monitoring
    • The balance between creating entirely new categories and building on established markets
    • The growing importance of clinical evidence and data in driving adoption and improving patient care

    Speakers:

    Glenn Hunzinger, US Health Industries Leader, PwC
    Darshana Zaveri, Co-founder and Managing Partner, Catalyst Health Ventures
    Geoff Pardo, General Partner, Gilde Healthcare
    Brent Hill, Managing Director, Medtech Strategy, PwC


    For more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.

    Show More Show Less
    34 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet